- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07595081
Propionic Acid for Multiple Sclerosis: Safety and Benefits (Pro-MADAI)
12. mai 2026 oppdatert av: Tobias Moser, Salzburger Landeskliniken
Propionic Acid in Multiple Sclerosis: Safety, Tolerability and Clinical Outcomes From the Pro-MADAI Study
The purpose of this study is to explore the long-term safety, tolerability, and clinical efficacy of propionic acid as an add-on therapy in multiple sclerosis (MS).
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study is a prospective, open-label extension of the placebo-controlled MADAI trial, including 22 patients with stable relapsing-remitting multiple sclerosis.
Participants received oral PA (500 mg twice daily) for an additional 9 months follow-up (FU).
Multimodal assessments included cognitive testing (SDMT), physical performance (9HPT, 10mWT), patient-reported outcome measurements PROMs (SF-36, FSMC, ESS, BDI-II), and serum NfL analysis.
Studietype
Intervensjonell
Registrering (Faktiske)
22
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
State of Salzburg
-
Salzburg, State of Salzburg, Østerrike, 5020
- Salzburger Landeskliniken
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Diagnosis of multiple sclerosis (MS)
- Clinically and radiologically stable MS in the previous 3 months
- Age between 18 and 70 years
- Positive finding for oligoclonal bands (OCBs)
- Written consent
- Blood collection at the beginning and end of the study for routine parameter examination as well as sample preservation (especially for measuring propionic acid levels)
- Negative pregnancy test for female participants of childbearing age
Exclusion Criteria:
- History of ongoing propionic acid (PA) supplementation exceeding 3 months
- Positive JC virus titer during natalizumab treatment
- Presence of severe active systemic disease
- Presence of acute neurological conditions
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Propionsyre 1000 mg
|
Patients will receive propionic acid as add on MS treatment.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum neurofilament light chain (NfL)
Tidsramme: 9 months
|
assessed as pg/ml
|
9 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Symbol Digit Modalities Test (SDMT)
Tidsramme: 9 months
|
Measuring cognitive processing speed in patients with MS.
Participants are instructed to match symbols to their respective numbers using a reference key.
The final score is determined by the number of correct symbol-number pairings completed within 90 seconds.
Higher scores indicate better cognitive abilities.
|
9 months
|
|
Nine-Hole Peg Test (9HPT)
Tidsramme: 9 months
|
Instrument to evaluate fine motor skills of the upper limbs and manual dexterity.
Performance is quantified by completion time, with shorter times reflecting better manual dexterity.
The participants insert and remove nine small pegs individually into nine corresponding holes on a rectangular board.
To improve reliability, this process was repeated twice for each hand.
|
9 months
|
|
10-Meter Walk Test (10mWT)
Tidsramme: 9 months
|
Evaluation of lower extremity function.
Participants were instructed to walk in a straight line at their fastest comfortable pace without running.
To avoid measurement bias caused by acceleration and deceleration phases, timing was restricted to the interval between the 2- and 8-meter marks, calculating walking speed over a 6-meter distance.
|
9 months
|
|
Short Form Health Survey (SF-36)
Tidsramme: 9 months
|
The SF-36 covers eight subscales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH).
These are transformed into two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
Both scores are calculated by combining the subscales using specific algorithms.
They reflect the overall physical and mental health status, respectively.
Each SF-36 domain is scored individually and transformed to a 0-100 scale, where 0 indicates poor health, and 100 represents optimal health.
Scores are interpreted as follows: excellent (>60), above average (51-60), average to slightly below average (41-50), moderately below average (31-40), and significant impairment (<30).
|
9 months
|
|
Fatigue Scale for Motor and Cognitive Functions (FSMC)
Tidsramme: 9 months
|
Fatigue was assessed using the 20-item Fatigue Scale for Motor and Cognitive Functions (FSMC).
Motor (FSMCmot) and cognitive (FSMCcog) aspects of fatigue were evaluated separately, and a total score (FSMCtot) was calculated.
This score ranges from 20 to 100.
Fatigue severity was classified as mild (≥43), moderate (≥53), or severe (≥63).
|
9 months
|
|
Epworth Sleepiness Scale (ESS)
Tidsramme: 9 months
|
Daytime sleepiness was evaluated using the Epworth sleepiness scale (ESS), an 8-item self-report questionnaire.
The ESS assesses the propensity to fall asleep or doze off briefly in different daily situations.
Higher scores indicate greater daytime sleepiness.
Each Item describes a hypothetical scenario, which participants rate on a 4-point scale (0-3).
This results in a total score ranging from 0 to 24 points.
Excessive daytime sleepiness was classified as mild (>10), moderate (>13), or severe (>16).
|
9 months
|
|
Beck Depression Inventory-II (BDI-II)
Tidsramme: 9 months
|
Depressive symptoms were assessed using the Beck Depression Inventory-Second Edition (BDI-II), a 21-item questionnaire.
It evaluates various aspects of depression, including libido, fatigue, appetite, decision-making ability, and feelings of guilt.
For each item, participants were asked to select one of four statements assessing symptom severity from absent (0) to severe (3).
|
9 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. august 2024
Primær fullføring (Faktiske)
1. mai 2025
Studiet fullført (Faktiske)
12. desember 2025
Datoer for studieregistrering
Først innsendt
3. mai 2026
Først innsendt som oppfylte QC-kriteriene
12. mai 2026
Først lagt ut (Faktiske)
19. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
19. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
12. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1026/2024-2
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .